Merit Medical Systems stock hits new 52-week low on NASDAQ amid analyst adjustments

The Merit Medical Systems stock (ISIN: US59001A1025) reached a new 52-week low of $67.17 on NASDAQ amid recent analyst target cuts, despite strong Q4 earnings beat and positive FY2026 guidance. German-speaking investors should watch for potential entry points in this medtech leader.

Merit Medical Systems, a key player in medical devices for cardiology and radiology, saw its stock plunge to a new 52-week low on Friday. Shares traded as low as $67.17 and closed at $67.4550 on NASDAQ in USD, down from the prior close of $68.33, on volume of 85,674 shares. This drop comes despite the company beating Q4 2025 earnings estimates with $1.04 EPS versus $0.96 expected and revenue of $393.94 million, up 10.9% year-over-year. FY2026 guidance of $4.010–4.150 EPS signals continued growth, yet analyst target reductions from firms like Piper Sandler and Needham have pressured the stock.

As of: 21.03.2026

By Dr. Elena Hartmann, Senior MedTech Analyst – Merit Medical Systems stock faces short-term pressure from target cuts, but robust earnings and guidance position it well for DACH investors seeking medtech exposure amid sector rotation.

Recent Earnings Strength Meets Market Skepticism

Merit Medical Systems reported solid Q4 results on February 24, 2026, exceeding expectations across key metrics. Earnings per share hit $1.04, surpassing the $0.96 consensus, while revenue climbed 10.9% to $393.94 million. This performance underscores the company's strength in peripheral vascular, cardiac intervention, and endoscopy products.

Management's FY2026 EPS guidance of $4.010 to $4.150 outpaces current analyst forecasts of $3.37 for the year, highlighting operational leverage. Net margins stood at 8.48% with return on equity at 13.82%, reflecting efficient capital use in a competitive medtech landscape.

For DACH investors, this beat signals resilience in a sector sensitive to procedure volumes and reimbursement dynamics. European medtech demand remains steady, with Merit benefiting from global diversification.

Analyst Actions Trigger Selloff

Wall Street's reaction has been mixed, with recent downward revisions fueling the decline. Piper Sandler cut its target from $113 to $106 on February 18, maintaining overweight. Needham followed with a reduction from $108 to $101 on February 25, keeping a buy rating. Despite this, the consensus remains Moderate Buy, with eight buys and three holds, targeting $103.33.

BTIG initiated coverage with a buy at $107 in early February, while Canaccord raised to $99 in December. These adjustments reflect caution on near-term growth amid macroeconomic headwinds, but long-term optimism persists on product innovation.

The stock's 50-day moving average of $78.58 and 200-day at $83.25 indicate it's well below trend lines, potentially attracting value hunters.

Financial Health Supports Recovery Potential

Balance sheet strength bolsters the investment case. Merit boasts a current ratio of 4.34, quick ratio of 2.95, and debt-to-equity of 0.46, indicating low leverage. Market cap sits at $4.02 billion, with P/E at 31.92 and PEG at 1.98, reasonable for medtech growth.

Beta of 0.62 suggests lower volatility, appealing for conservative portfolios. Institutional interest remains high, with new stakes from Tudor Investment, Assenagon, and Norges Bank in recent quarters.

In medtech, these metrics highlight execution risk mitigation through strong liquidity and modest debt, key for R&D and acquisitions.

Why DACH Investors Should Monitor Closely

German-speaking investors in Germany, Austria, and Switzerland find Merit compelling due to Europe's aging population driving demand for vascular access devices. DACH healthcare spending emphasizes minimally invasive procedures, aligning with Merit's portfolio.

With NASDAQ-listed shares in USD, accessibility via local brokers is straightforward. The current dip below $70 offers a potential entry versus the $103 analyst target, amid euro strength considerations. Sector peers face similar pressures, but Merit's beats differentiate it.

Regulatory stability in EU markets supports expansion, making it relevant for diversified medtech allocations.

Key Sector Catalysts Ahead

Medtech investors eye procedure recovery post-pandemic and innovation pipelines. Merit's focus on embolics, balloons, and aspiration systems positions it for cardiology growth. Upcoming Q1 2026 earnings on April 24 could reaffirm guidance.

Global revenue mix reduces US-centric risks, with international sales contributing significantly. AI integration in imaging and new product launches could drive margins higher.

For DACH, Europe's push for value-based care favors Merit's cost-effective devices over high-end competitors.

Risks and Open Questions

Despite strengths, headwinds loom. Analyst cuts signal concerns over slowing growth or margin compression from supply chain issues. Macro factors like interest rates impact hospital capex.

Competition from larger players like Boston Scientific intensifies, while reimbursement changes pose threats. The stock's low beta offers defense, but prolonged sector rotation could extend the downtrend.

Investors must weigh execution on guidance against these uncertainties, monitoring volume for reversal signals.

Strategic Positioning for Long-Term Gains

Merit's track record of beats – seven straight quarters – builds credibility. Trailing EPS of $1.97 and forward growth to $3.75 project 11.28% EPS expansion.

DACH portfolios benefit from US medtech diversification, with currency hedges available. At current levels on NASDAQ in USD, the risk-reward skews positive versus consensus targets.

Stay tuned for institutional flows and technical bounces as catalysts.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.